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Abstract
AIM: Hepatit is C virus often establ ishes chronic 
infections. Recent studies suggest that viral and bacterial 
infections are more common in HCV-infected patients 
compared to controls. Pathogens are recognized by 
Toll-like receptors (TLRs) to shape adaptive and innate 
immune responses. 
METHODS: In this study, to assess the ability of HCV-
infected host to recognize invading pathogens, we 
investigated Toll-like receptor expression in innate 
(monocytes) and adaptive (T cells) immune cells by real-
time PCR. 
RESULTS: We determined that RNA levels for TLRs 
2, 6. 7, 8, 9 and 10 mRNA levels were upregulated in 
both monocytes and T cells in HCV-infected patients 
compared to controls. TLR4 was only upregulated in T 
lymphocytes, while TLR5 was selectively increased in 
monocytes of HCV-infected patients. MD-2, a TLR4 co-
receptor, was increased in patients’ monocytes and T 
cells while CD14 and MyD88 were increased only in 
monocytes. 
CONCLUSION: Our data reveal novel details on TLR 
expression that likely relates to innate recognition 
of pathogens and immune defense in HCV-infected 
individuals.
© 2006 The WJG Press. All rights reserved.
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INTRODUCTION
Hepatitis C virus (HCV) infection is the cause of  chronic 
hepatitis in more than 4 million people in the USA[1]. 
Patients with chronic HCV infection experience a various 
severity of  liver diseases ranging from mild hepatitis to 
cirrhosis and hepatocellular carcinoma. Liver cirrhosis that 
appears decades after the initial infection often predisposes 
to spontaneous bacterial peritonitis and sepsis[2]. HCV 
is the most frequent indication for liver transplantation, 
and transplant recipients suffer from recurrent HCV and 
infections associated with immunosuppression[3]. HCV, 
a blood borne pathogen, is frequently associated with 
human immunodefi ciency virus (HIV) infection acquired 
through the same route of  invasion[4]. According to clinical 
data, HCV is not only the cause of  morbidity due to liver 
disease, but it is also associated with other infections. A 
recent study by El-Sarag et al[5] suggested that infections 
with other viral and bacterial pathogens were more 
common in HCV-infected patients who otherwise had 
no immunocompromise compared to non-HCV infected 
controls. The pathogens causing infections at a higher rate 
in HCV patients included cytomegalovirus, cryptococcus, 
Mycobacterium tuberculosis and those causing sexually 
transmitted diseases[5]. It remains to be evaluated whether 
recognition of  pathogens and/or mounting appropriate 
immune responses is impaired in HCV infection.
Bacterial and viral pathogens are recognized as “danger” 
signals by the family of  Toll-like receptors (TLRs) that alert 
innate immunity against the invading pathogens[6]. The 
known 11 mammalian TLRs have distinct extracellular do-
mains but share common intracellular mechanisms of  cell 
activation that culminate in production of  inflammatory 
cytokines. Each TLR has specifi c ligands, which allow the 
host to sense a wide diversity of  pathogens. TLR1, TLR6 
and possibly TLR10 form heterodimers with TLR2 to 
recognize fungi (Sarcomyces cereviciea, Candida albicans, 
and Aspergillus fumigatus), parasites (Trypanosoma cruzi), 
Gram positive bacteria-derived peptidoglycan (PGN) and 
bacterial lipoproteins, lipoarabinomannan from Mycobac-
terium tuberculosis, Treponema pallidum-derived glycolipid 
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and lipoteichoic acid[6,7]. TLR2 can also recognize certain 
viruses such as cytomegalovirus, measles virus and core 
and NS3 proteins of  HCV[8-10]. TLR3 recognizes poly(I-C) 
and double-stranded viral RNA, whereas TLR4 agonists 
include Gram-negative bacterial LPS, respiratory syncytial 
virus, Cryptococcus neoformans and the plant product 
Taxol[6,7,11]. Bacterial fl agellin has been identifi ed as a TLR5 
ligand, synthetic components imiquimod and resiquimod 
848 and single stranded RNA stimulate TLR 7 and 8, while 
unmethylated CpG-containing DNA and herpes simplex 
virus have been identifi ed as TLR9 agonists[6,7,12]. 
The presence of  TLRs was originally discovered in 
innate immune cells[13]. Monocytes express all TLRs of  
which TLRs 1, 2, and 4 are present at high levels[14]. Latest 
research, however, indicates that TLR expression is not re-
stricted to innate immune cells and TLRs can be detected 
in adaptive immune cells as well as in parenchymal cells. In 
particular, T cells express all TLRs at low levels with the 
exception of  TLR5, which is present abundantly[14, 15].
In order to dissect the ability of  HCV-infected host to 
respond to invading pathogens, we investigated Toll-like 
receptor expression in innate (monocytes) and adaptive 
(T cells) immune cells. We determined that TLR2, 7, 8, 9 
and 10 were upregulated in both immune compartments in 
HCV-infected patients compared to controls. In addition, 
TLR4 was upregulated in lymphocytes and TLR6 was up-
regulated in monocytes only. Our data reveal new insights 
into immune defense of  HCV-infected individuals.
MATERIALS AND METHODS
Blood donors 
Healthy individuals (controls, n = 14) and treatment-naïve 
patients chronically infected with hepatitis C virus (HCV 
patients, n = 14) were enrolled in the study. All individuals 
were free of  acute infections. The study was approved 
by the Committee for the Protection of  Human Subjects 
in Research at the University of  Massachusetts Medical 
School and informed consent was obtained. The clinical 
characteristics of  the patients are detailed in Table 1. The 
blood was collected from cubital vein with anti-coagulant 
(heparin sodium) and processed immediately. Controls and 
patients were matched for age and gender where possible.
Cells
Peripheral blood mononuclear cells (PBMCs) were 
separated by centrifugation on Ficoll gradient. In order 
to separate monocytes from lymphocytes, the PBMCs 
were plated (107/well in 2 mL of  RPMI1640 media 
supplemented with 10 % FBS) in 6 well plates (Corning, 
Corning, NY) and incubated at 37 ℃ in 50 ml/L CO2 
atmosphere for 3 h. Monocytes were separated based on 
their adherence to plastic and the purity of  the population, 
based on CD14 expression, was greater than 95% as 
determined by flow cytometry (data not shown). Non-
adherent cells were washed and T lymphocytes were 
purifi ed using T cell negative isolation kit (Dynal Biotech 
Inc, Lake Success, NY), as manufacturer recommended. 
Briefl y, non-adherent cells were incubated with a cocktail 
of  antibodies for CD14, CD16a, CD16b, CD56, HLA 
class II DR/DP and CD235A, followed by incubation with 
depletion magnetic Dynabeads. The non-T cells bound to 
the Dynabeads and were separated in a strong magnetic 
field while T cells were washed and subjected to RNA 
extraction. 
Real-time PCR
Total cellular RNA was extracted using RNeasy kits (Qia-
gen, Valencia, CA), according to manufacturer’s recom-
mendations. All samples were co-processed to eliminate 
technical variations. Equal amounts of  RNA from con-
trols and HCV-infected patients were analyzed. Reverse 
transcription of  1 μg of  RNA into cDNA was performed 
using reverse transcription System (Promega, Madison, 
WI). The real-time PCR primers were synthesized by IDT 
(Coralville, Iowa), except for 18S (Quantum RNA Classic 
II 18S Internal Standard, Ambion, Austin, TX). The real-
time PCR was performed using the ICycler (Biorad Labo-
ratories, Hercules, CA). The PCR primers are described 
in Table 2. The reaction mixture contained 12.5 μL qPCR 
Table 1 Patient characteristics
Parameter Value
Gender (male/female) 12/2
Age (yr) 44 ± 12
Duration of disease > 10 yr 5
Unknown 9
Viral load (by QUNT BDNA, IU/ml) 1 x 107 ± 0.78 x 107
Viral genotype               (by 
PCR)
1a 5
1b 4
3a 3
4a 2
Plasma SGOT (ALT) levels (IU/mL) 110 ± 86
Plasma SGPT (AST) levels (IU/mL) 102 ±60
Primer identifi cation Sequence
TLR1
Forward 5'-GGG TCA GCT GGA CTT CAG AG-3'
Reverse 5'-AAA ATC CAA ATG CAG GAA CG-3'
TLR2
Forward 5'-GCC TCT CCA AGG AAG AAT CC-3'
Reverse 5'-TCC TGT TGT TGG ACA GGT CA-3'
TLR3
Forward 5'-GTG CCA GAA ACT TCC CAT GT-3'
Reverse 5'-TCC AGC TGA ACC TGA GTT CC-3'
TLR4
Forward 5'-AAG CCG AAA GGT GAT TGT TG-3'
Reverse 5'-CTG AGC AGG GTC TTC TCC AC-3'
TLR5
Forward 5'-TTG CAT CCA GAT GCT TTT CA-3'
Reverse 5'-TTC AAC TTC CCA AAT GAA GGA-3'
TLR6
Forward 5'-GAA CAT GAT TCT GCC TGG GT-3'
Reverse 5'-GCT GTT CTG TGG AAT GGG TT-3'
TLR7
Forward 5'-AAT GTC ACA GCC GTC CCT AC-3'
Reverse 5'-GCG CAT CAA AAG CAT TTA CA-3'
TLR8
Forward 5'-TGT GAT GGT GGT GTC TCA AT-3'
Reverse 5'-ATG CCC CAG AGG CTA TTT CT-3'
TLR9
Forward 5'-ATT CTG ACT TTG CCC ACC TG-3'
Reverse 5'-GCT GAG GGA CAG GGA TAT GA-3'
TLR10
Forward 5'-GGC CAG AAA CTG TGG TCA AT-3'
Reverse 5'-AAA TGA CTG CAT CCA GGG AG-3'
MyD88
Forward 5'-GAG CGT TTC GAT GCC TTC AT-3'
Reverse 5'-CGG ATC ATC TCC TGC ACA AA-3'
MD2
Forward 5'-ATT CCA AGG AGA GAT TTA AAG CAA TT-3'
Reverse 5'-CAG ATC CTC GGC AAA TAA CTT CTT-3'
CD14
Forward 5'-CGC TCC GAG ATG CAT GTG-3'
Reverse 5'-TTG GCT GGC AGT CCT TTA GG-3'
Table 2  Real-time PCR primers
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MasterMix Plus with 2 x SYBR Green  (Eurogentec, Sera-
ing, Belgium), 0.5 μmol/L of  forward and reverse primer 
and 1 μL of  cDNA (corresponding to 50 ng of  RNA) in 
a total volume of  25 μL. All amplifi cations and detections 
were carried out in a BioRad optical 96-well reaction plate 
with optical tape. At each cycle, accumulation of  PCR 
products was detected by monitoring the increase in fl uo-
rescence by dsDNA-binding SYBR Green. After the PCR 
was performed, a dissociation/melting curve was con-
structed in the range of  55°C to 95°C. Data were analyzed 
using the Biorad ICycler software. As a fi rst step in data 
analysis 18S was used for normalization of  all experiments 
(normalizer) and it was closely compared between controls 
and HCV patients. For second step in data analysis we 
used comparative Ct method (∆∆Ct method) with the fol-
lowing formula: ∆Ct = Ct (target, TLR) - Ct (normalizer, 
18S). The comparative ∆∆Ct calculation involved fi nding 
the difference between ∆Ct of  HCV patient and the mean 
value of  the ∆Ct from normals for each analyzed mol-
ecule. Fold increase in the expression of  specifi c mRNA in 
HCV patients compared to normal controls was calculated 
as 2-(∆∆Ct).
Statistical analysis 
The non-parametric Wilcoxon test from StatView on a G4 
Machintosh platform (Cuppertino, CA) was employed to 
determine the statistical difference between controls and 
HCV patients. 
RESULTS
HCV-infected patient selection and their characteristics  
Our study population included patients with chronic 
HCV infection but without cirrhosis or cancer, thus, 
HCV infection-specific imprints on the immune system 
were present but cirrhosis or cancer-related non-specifi c 
immune alterations could be excluded. All patients 
in the study had viremia and elevated levels of  liver 
transaminases consistent with chronic hepatitis. Patients 
infected with different viral genotypes (1A, 1B, 3A and 
4A) were included, as viral genotype could affect host 
immune response[16].  Our patients had never been treated 
with anti-viral therapy, thus possible infl uence of  therapy 
on TLR expression was eliminated. This is important 
because Ribavirin was shown to augment signaling in TLR-
transfected cells[17].
Monocytes of HCV-infected patients express higher levels 
of TLRs 2, 3, 5, 6, 7, 8, 9 and 10 RNA compared to controls 
Chronic HCV infection is associated with increased serum 
levels of  infl ammatory cytokines[18]. Blood monocytes and 
tissue macrophages are major sources of  these cytokines. 
We recently reported increased monocyte production of  
TNFα in patients with chronic HCV infection[10]. In this 
study, we used real-time PCR to evaluate TLR expression 
in monocytes of  HCV-infected patients and healthy con-
trols. Monocytes both from controls and HCV-infected 
patients expressed TLRs 1-10 (Figure 1), as expected based 
on previous studies[14]. We found that monocytes from pa-
tients with chronic HCV infection expressed signifi cantly 
higher levels of  RNA coding for TLR2, TLR5, TLR6 and 
TLR10. Different TLRs reside at different locations in the 
cell. TLRs 1, 2, 4, 5, 6 and 10 are expressed mostly on the 
surface of  the cellular membrane, while TLRs 3, 7, 8 and 9 
are localized inside the cells[6,7]. Surprisingly, we found that 
not only some outer cellular membrane-associated TLRs, 
but also the intracellularly localized TLRs, TLRs 7, 8 and 
9, were upregulated in HCV patients’ monocytes. The level 
of  TLR3 mRNA was also significantly higher in HCV-
infected patients compared to controls.
Ligand recognition and signaling of  TLR2 and TLR4 is 
augmented by co-receptors[6,7]. Thus, we further analyzed 
the expression of  TLR co-receptors and adaptors in 
both controls and HCV-infected patients. We found 
that the mRNA level of  CD14, a co-receptor for TLR2 
and TLR4, was upregulated in HCV patients compared 
to controls (Figure 2). In addition to CD14, MD-2 is 
another accessory protein of  the TLR4 that is necessary 
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Figure 1 Higher TLRs 2, 5, 6, 7, 8, 9 and 10 RNA expression by monocytes of HCV-infected patients compared to controls. RNA was purifi ed from adherence-isolated 
monocytes and real-time PCR for TLRs 1-10 and 18 S RNA (as endogenous control) was performed as described in Materials and Methods. For each individual, TLR-
coding RNA expression was normalized to corresponding 18 S RNA. Results are expressed as fold increase of each TLR in HCV-infected patients compared to controls. 
Results are from 14 HCV-infected patients and 14 controls.
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for assembling the TLR4-containing receptor complex to 
sense low quantities of  lipopolysaccharide[19]. We found 
that MD2 mRNA was expressed at significantly higher 
levels in monocytes of  HCV infected patients compared to 
controls. The mRNA for MyD88, an intracellular adaptor 
molecule that is recruited to the intracellular domain of  
TLRs 2, 4, and 9 upon engagement with specifi c ligands, 
was also higher in patients compared to controls. These 
results suggest that increased RNA expression of  various 
TLRs and their co-receptors may predispose monocytes to 
increased TLR-mediated activation in chronic HCV.
Lymphocytes of HCV-infected patients express higher lev-
els of TLRs compared to controls  
We next investigated the expression of  TLRs in CD3+ 
T cells of  the adaptive immune cells. T cells from con-
trols and HCV infected patients expressed mRNA for 
TLRs1-10 (Figure 3) as expected based on previous pub-
lications[14,15]. There was no CD14 mRNA expressed in T 
lymphocytes of  either controls or HCV-infected patients, 
confirming the purity of  the cell population (data not 
shown). We found that levels of  RNA coding for mem-
brane-localized TLR1, 2, 4, 6 and 10 as well as the TLR4 
co-receptor, MD2, were signifi cantly higher in HCV infect-
ed patients compared to controls. No differences in levels 
of  RNA coding for MyD88 or TLR3 and TLR5 (Figure 3) 
between controls and patients were identifi ed. In contrast, 
the RNA levels of  intracellularly localized TLRs 7, 8 and 
9 were signifi cantly higher in T lymphocytes of  HCV in-
fected patients compared to controls. 
DISCUSSION
Monocytes and lymphocytes, respectively, are representa-
tive populations of  innate and adaptive immunity and their 
cooperation is required to recognize, limit and eliminate 
invading microbes[20].  Here we show that patients infected 
with HCV have a unique pattern of  TLR expression in 
both the innate and adaptive immune compartments and 
have elevated RNA expression of  both membrane-asso-
ciated and intracellularly localized TLRs. Recent reports 
demonstrate that HCV-infected patients have a higher 
prevalence of  infections with cytomegalovirus, Cryptococ-
cus, Mycobacterium tuberculosis and sexually transmitted 
diseases compared to controls[5]. Recognition of  these 
pathogens requires TLR-mediated signals. For example, 
sensing of  Cryptococcus by the innate immune system 
requires TLR2, TLR4, MyD88 and CD14[21], while TLR2 
and TLR4 are instrumental in the host’s response against 
Mycobacteria[22]. The pathogens implicated in sexually-
transmitted diseases, found more often in HCV-infected 
patients, are also recognized by TLR. Chlamydia elicits 
an unusual set of  infl ammatory responses via TLR2 and 
TLR4 in vivo, and TLR2 is essential for development of  
oviduct pathology in chlamydial genital tract infection[23], 
while Neisseria gonorrhoeae stimulates cytokine release 
and NF-κB activation in epithelial cells in a TLR2-depen-
dent manner[24]. In addition, some TLRs may play a protec-
tive or even therapeutic role in defense against sexual dis-
ease pathogens: TLR3 agonists protect against genital her-
pes infection[25] and Imiquimod, a TLR7&8 ligand and the 
fi rst FDA-approved imidazoquinoline, has been approved 
for the therapy of  genital warts[26]. Increased expression of  
TLR2 and TLR4 is a bad prognostic factor in patients with 
sepsis[27], while low TLR expression may protect the host 
against excessive infl ammation and tissue damages[28], thus, 
differential expression of  TLRs in HCV infected patients 
may contribute to susceptibility to infections as well as to 
the underlying disease progression and this remains to be 
determined. 
The observation of  increased expression of  TLR2 in 
patients was not totally unexpected, since chronic HCV in-
fection is associated with elevated levels of  circulating LPS, 
which upregulates the expression of  TLR2 in different cell 
types, including monocytes[21-23]. We have previously shown 
that HCV core and non-structural protein 3 (NS3), activate 
cells through TLR2[10]. We found elevated levels of  the 
TLR co-receptors, CD14 and MD2, and adaptor molecule 
MyD88, in HCV-infected patients compared to controls, 
suggesting that MyD88-mediated TLR signal transduction 
may also be affected in patients. Indeed, we have previ-
ously found that monocytes from HCV infected patients 
are hyper-responsive to stimulation with TLR4 and TLR2 
ligands[10,32]. Although we did not fi nd a role for CD14 in 
TLR2-mediated cell activation by HCV-derived core and 
NS3 proteins (unpublished data), increased CD14 expres-
sion may be relevant to cell activation mediated by other 
TLR2 and TLR4 ligands, as previously reported for LPS, 
lipoteichoic acid and even viruses[9].  
Intracellularly-localized TLR 3, 7, 8 and 9 are of  spe-
cifi c interest in patients with chronic viral infections since 
these receptors can recognize virus-derived molecular 
patterns[6,7]. We found that TLR3 expression was higher in 
monocytes of  HCV-infected patients compared to con-
trols. TLR3 is a sensor for double-stranded RNA and it 
has been implicated in pathogenesis of  viral infections[33,34]. 
Synthetic RNA compounds, such as polyI:C activate 
cells expressing TLR3[35]. In a recent study by Edelmann 
et al [36] the role of  TLR3 was investigated in four differ-
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ent infectious viral models [lymphocytic choriomeningitis 
virus (LCMV), vesicular stomatitis virus (VSV), murine 
cytomegalovirus (MCMV), and reovirus in TLR3-/- mice]. 
The investigators found that TLR3 is not always required 
for the generation of  effective antiviral responses, as the 
absence of  TLR3 did not alter either viral pathogenesis or 
host's generation of  adaptive antiviral responses to those 
viruses. Interestingly, intracellular transduction of  poly(I:
C) initiates activation of  an IFN response in a TLR3-
independent manner, thus limiting the role of  TLR3 in the 
IFN pathway[35]. A recent report by Li et al [34] indicates that 
HCV may use TLR3 pathway to evade immune surveil-
lance via HCV NS3/4A protease-mediated cleavage of  the 
TLR3 adaptor protein TRIF.  Furthermore, HCV NS3/4A 
interferes with retinoic acid-inducible gene-I (RIG-I), a 
key factor in TRIF-independent signaling[37]. Our fi nding 
of  increased TLR3 mRNA levels in monocytes of  HCV 
patients awaits further investigation. It is tempting to 
speculate that HCV RNA may trigger cellular activation 
via TLR3, and indeed, all our patients had high levels of  
viremia, however no clear relationship between HCV RNA 
levels and TLR3 expression has been proven to date. 
TLR7 and TLR8 are stimulated by synthetic com-
pounds imiquimod and resiquimod 848[6,7,35]. In a recent 
publication, Lund et al[12] showed that TLR7 recognizes 
the single-stranded RNA viruses, vesicular stomatitis virus 
and infl uenza virus.  The recognition of  these viruses by 
plasmacytoid dendritic cells and B cells through TLR7 re-
sults in cellular activation and the production of  cytokines. 
However, the specifi c role of  TLR7 and TLR8 in innate 
immune response to HCV is yet to be understood. HCV is 
a single stranded RNA virus, thus, it could theoretically act 
as a ligand for TLR7. Our data show that TLR7 mRNA 
is signifi cantly upregulated in HCV patients compared to 
controls, and all patients had detectable levels of  HCV 
RNA in their plasma, thus suggesting that TLR7 may be 
implicated in the pathogenesis of  HCV infection.
We found that both monocytes and T cells of  HCV-
infected patients expressed elevated levels of  TLR9 
mRNA compared to controls. CpG-containing DNA acts 
as a stimulatory ligand for TLR9[6,7,29,35]. TLR9 is regulated 
at the transcriptional level by multiple nuclear regulatory 
factors, co-repressors and co-activators, including CREB1, 
Ets2, Elf1, Elk1, and C/EBP and HCV may regulate these 
transcription factors[38,39]. Toll-like receptors 9 and 3 are 
essential components of  innate immune defense against 
cytomegalovirus infection in mice[40]. While we found that 
TLR9 mRNA was upregulated in patients, others have 
shown that infections with cytomegalovirus are more fre-
quent in HCV-infected patients compared to controls[5]. It 
remains to be elucidated if  the increased TLR9 RNA levels 
in monocytes or T cells have a role in increased suscepti-
bility to infections with CMV, as seen in HCV patients.
To date little is known about the role of  TLR expres-
sion in T cells of  the adaptive immune compartment. 
Caramalho et al[41] recently reported that LPS, a TLR4 
ligand, promotes survival of  activated CD4+ cells and 
stimulates regulatory T cell  (T reg) activity. Here we found 
that TLR4 mRNA expression was higher in HCV-infected 
patients compared to controls only in lymphocytes, but 
not in monocytes.  It is tempting to speculate that elevated 
levels of  TLR4 and its co-receptor, MD-2, in patients’ T 
cells may provide ongoing activation in the presence of  
serum LPS found in chronic HCV and provide preferen-
tial survival signals for T regs[30]. Recent data suggest a role 
for T regs in immune alterations associated with chronic 
HCV. Cabrera et al[42] reported that Tregs appear to play a 
role in viral persistence by suppressing HCV-specifi c T cell 
responses in a cell-cell contact manner, while MacDonald 
et al [43] showed that Tregs could be induced against the 
same epitopes on the HCV core protein.
A limitation of  our study is that it did not distinguish 
between TLR expression in CD4+ and CD8+ T cells. Dif-
ferential CD4+ and CD8+ T-cell responsiveness in hepatitis 
C virus infection has been reported, thus, leading to the 
hypothesis that if  TLRs are of  any functional role in T 
cells, there may be differences in TLR expression between 
CD4+ and CD8+ T cells in HCV-infected patients. Due to 
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the presence of  anti-CD56 mAbs in the separation cock-
tail, we also lost CD56+ T cells, known as gamma delta, 
with an important role in HCV infection[44].
In conclusion, we showed that patients with chronic 
HCV infection express elevated levels of  selected TLRs 
in both adaptive and innate compartments of  the immune 
system. Our data may suggest additional therapeutic targets.
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